Does I-131-MIBG underestimate skeletal disease burden in neuroblastoma?

Simple item page
dc.contributor.authorBarai, Sen_US
dc.contributor.authorBandopadhayaya, G Pen_US
dc.contributor.authorMalhotra, Aen_US
dc.contributor.authorAgarwal, Sen_US
dc.contributor.authorKumar, Ren_US
dc.contributor.authorDhanapathi, Hen_US
dc.date.accessioned2004-10-30en_US
dc.date.accessioned2009-06-02T10:12:44Z
dc.date.available2004-10-30en_US
dc.date.available2009-06-02T10:12:44Z
dc.date.issued2004-10-30en_US
dc.description.abstractBACKGROUND: Controversy persists as to the need for both MIBG and bone scanning in routine evaluation of neuroblastoma. AIM: To compare the efficacy of I-131- metaiodobenzylguanidine (MIBG) scan against that of conventional Tc99m- methylene diphosphonate (MDP) bone scan for the detection of skeletal deposition of neuroblastoma. METHODS AND MATERIAL: The study included 57 patients (36 boys, 21 girls: age range 1-14 years) of neuroblastoma who underwent both bone scan with Tc99m-MDP and I-131-MIBG scan within 15 days of each other at presentation and during follow-up. RESULTS: At presentation 11(19.2%) patients had evidence of skeletal metastases on MDP scan against 7 patients who showed bony secondaries on MIBG scan. Of the 7 patients, with positive MIBG and MDP scans, MDP scan detected 11 sites whereas MIBG scan detected 7 sites. On follow-up study, 3 patients with initial abnormal MDP scan but normal MIBG scan, developed skeletal metastases detectable on MIBG scan, whereas 3 of the 46 patients who had normal MDP and MIBG scan at presentation; developed skeletal metastases detectable on MDP scan. MIBG scan was concordant in 2 of them but was normal in the third patient. CONCLUSION: I-131-MIBG underestimates skeletal disease burden in neuroblastoma. Therefore, Tc99m-MDP bone scan should remain a part of routine assessment of patients with neuroblastoma.en_US
dc.description.affiliationDepartment of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India. danzig@rediffmail.comen_US
dc.identifier.citationBarai S, Bandopadhayaya GP, Malhotra A, Agarwal S, Kumar R, Dhanapathi H. Does I-131-MIBG underestimate skeletal disease burden in neuroblastoma? Journal of Postgraduate Medicine. 2004 Oct-Dec; 50(4): 257-60; discussion 260-1en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/115362
dc.language.isoengen_US
dc.source.urihttps://www.jpgmonline.comen_US
dc.subject.mesh3-Iodobenzylguanidine --diagnostic useen_US
dc.subject.meshAdolescenten_US
dc.subject.meshBone Neoplasms --radionuclide imagingen_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshMaleen_US
dc.subject.meshNeuroblastoma --radionuclide imagingen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRadiopharmaceuticals --diagnostic useen_US
dc.subject.meshTechnetium Tc 99m Medronate --diagnostic useen_US
dc.titleDoes I-131-MIBG underestimate skeletal disease burden in neuroblastoma?en_US
dc.typeComparative Studyen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of Postgraduate Medicine